ATE507211T1 - Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer - Google Patents

Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer

Info

Publication number
ATE507211T1
ATE507211T1 AT07757668T AT07757668T ATE507211T1 AT E507211 T1 ATE507211 T1 AT E507211T1 AT 07757668 T AT07757668 T AT 07757668T AT 07757668 T AT07757668 T AT 07757668T AT E507211 T1 ATE507211 T1 AT E507211T1
Authority
AT
Austria
Prior art keywords
beta
hydroxysteroid dehydrogenase
inhibitors
triazine
dehydrogenase type
Prior art date
Application number
AT07757668T
Other languages
English (en)
Inventor
Jun Li
Jeffrey A Robl
Lawrence J Kennedy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE507211T1 publication Critical patent/ATE507211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C07D253/10—Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT07757668T 2006-03-01 2007-03-01 Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer ATE507211T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77815906P 2006-03-01 2006-03-01
US11/679,898 US7834178B2 (en) 2006-03-01 2007-02-28 Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
PCT/US2007/063012 WO2007103694A2 (en) 2006-03-01 2007-03-01 Triazine 11-beta hydroxysteroid dehydrogenase type i inhibitors

Publications (1)

Publication Number Publication Date
ATE507211T1 true ATE507211T1 (de) 2011-05-15

Family

ID=38375689

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07757668T ATE507211T1 (de) 2006-03-01 2007-03-01 Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer

Country Status (5)

Country Link
US (1) US7834178B2 (de)
EP (1) EP1989190B1 (de)
AT (1) ATE507211T1 (de)
DE (1) DE602007014186D1 (de)
WO (1) WO2007103694A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
WO2017034994A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
HK1257102A1 (zh) 2015-08-21 2019-10-11 Portola Pharmaceuticals, Inc. 苯基哌嗪前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)调节剂及其应用
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2018234488A1 (en) 2017-06-23 2018-12-27 Basf Se Substituted cyclopropyl derivatives
RU2020105929A (ru) 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. Способы и композиции для модулирования сплайсинга
US11530207B2 (en) 2018-04-10 2022-12-20 Skyhawk Therapeutics, Inc. Compounds for the treatment of cancer
CN110746429B (zh) * 2018-12-10 2022-11-25 广州华睿光电材料有限公司 含金刚烷的化合物、高聚物、混合物、组合物及电子器件
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
EP3920926A4 (de) 2019-02-05 2022-10-19 Skyhawk Therapeutics, Inc. Verfahren und zusammensetzungen zur modulierung der spleissung
CN119638696A (zh) 2019-02-06 2025-03-18 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
BR112021018664A2 (pt) 2019-04-02 2021-11-23 Array Biopharma Inc Inibidores de proteína tirosina fosfatase
US20220267269A1 (en) * 2019-06-14 2022-08-25 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2024097598A1 (en) * 2022-11-02 2024-05-10 Merck Sharp & Dohme Llc Triazines useful as inhibitors of nod-like receptor protein 3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3836531A (en) * 1969-12-11 1974-09-17 Asahi Chemical Ind Synthetic nacreous pigments and method for production thereof
BE786840A (fr) * 1971-07-29 1973-01-29 Bayer Ag Procede de preparation de 1,2,4-triazine -5-ones
DE2802488A1 (de) * 1978-01-20 1979-07-26 Bayer Ag 3-azolyl-benzotriazine und -benzotriazin-1-oxide, verfahren zu ihrer herstellung, sowie ihre verwendung zur bekaempfung von pflanzenkrankheiten
EP0186868A3 (en) 1985-01-02 1988-09-21 Eastman Kodak Company Photographic element and process for providing metal complex color images
US4701420A (en) 1985-04-01 1987-10-20 Eastman Kodak Company Analytical compositions, elements and methods utilizing reduction of ferric ion chelates to form detectable dyes
US5624925A (en) * 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
US5069708A (en) * 1989-07-14 1991-12-03 Basf Aktiengesellschaft Pyrimido(5,4-e)-as-triazine-5,7(6H,8H)-diones
CA2041800C (en) 1990-07-31 2003-04-29 Claudia C. Pierce On-line iron (ii) concentration monitoring to continuously determine corrosion in boiler systems
US5110347A (en) * 1990-11-26 1992-05-05 E. I Du Pont De Nemours And Company Substituted fused heterocyclic herbicides
JPH0551369A (ja) * 1991-05-21 1993-03-02 Sumitomo Chem Co Ltd ６−置換−３，５−ジフエニル−１，２，４−トリアジン誘導体、それを有効成分とする除草剤およびその製造中間体
US5484612A (en) * 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
US5827850A (en) * 1995-09-25 1998-10-27 Sanofi Pharmaceuticals, Inc. 1,2,4-benzotriazine oxides formulations
CO5210943A1 (es) * 1999-05-04 2002-10-30 Novartis Ag Compuestos plaguicidas derivados de triazina, composiciones para el control de plagas que comprenden dicho compuesto y cuando menos un auxiliar y metodos para controlar plagas
AU2001288432A1 (en) * 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1397351T3 (da) * 2001-06-01 2010-01-18 Hoffmann La Roche Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
EP1485100B1 (de) * 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azolylaminoazine als proteinkinasehemmer
ES2289279T3 (es) * 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
US7304061B2 (en) * 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
DE60311812T2 (de) * 2002-07-15 2007-11-22 Janssen Pharmaceutica N.V. 3-furylanaloga von toxoflavin als kinaseinhibitoren
EP1546117A2 (de) * 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Proteinkinaseinhibitoren und deren verwendungen
AU2003286876A1 (en) * 2002-11-01 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
EP1833820A1 (de) * 2004-12-23 2007-09-19 Vertex Pharmaceuticals Incorporated Selektive inhibitoren der erk-proteinkinase und anwendungen davon
CN101146796A (zh) * 2005-01-26 2008-03-19 先灵公司 作为蛋白激酶抑制剂用于治疗癌症的3-(吲唑-5-基)-(1,2,4)三嗪衍生物及相关化合物
EP1871762A2 (de) * 2005-04-18 2008-01-02 Neurogen Corporation Substituierte heteroaryle als cb1-antagonisten
AU2006265201C1 (en) 2005-07-05 2010-12-09 F. Hoffmann-La Roche Ag Pyridazine derivatives
WO2007038452A1 (en) 2005-09-28 2007-04-05 Merck & Co., Inc. Process for synthesizing 1,2,4-triazoles
JP2009510013A (ja) * 2005-09-30 2009-03-12 エフ．ホフマン−ラ ロシュ アーゲー Ｎｎｒｔ阻害剤
CN101291672A (zh) 2005-10-20 2008-10-22 默克公司 用作11β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物

Also Published As

Publication number Publication date
WO2007103694A2 (en) 2007-09-13
US7834178B2 (en) 2010-11-16
DE602007014186D1 (de) 2011-06-09
EP1989190B1 (de) 2011-04-27
US20070207985A1 (en) 2007-09-06
EP1989190A2 (de) 2008-11-12
WO2007103694A3 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
ATE507211T1 (de) Triazin-11-beta-hydroxysteroid-dehydrogenase- artige hemmer
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
EA201000563A1 (ru) Триазолпиридиновые ингибиторы 11-бета- гидроксистероид - дегидрогеназы типа i
TW200716116A (en) Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors
WO2006113261A3 (en) Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
EA200900344A1 (ru) Циклические ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i
EA201001412A1 (ru) Ингибиторы киназы pim и способы их применения
EA200900821A1 (ru) Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
UA106054C2 (uk) ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИМІДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ TРK-КІНАЗИ
CR11803A (es) Pirrolopiridinas como inhibidores de cinasa
EA200700220A1 (ru) Имидазотриазины в качестве ингибиторов протеинкиназы
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
SG132683A1 (en) Imidazopyrazine tyrosine kinase inhibitors
MX338557B (es) Compuesto heterociclico y uso del mismo.
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
PT1771178E (pt) Utilização de k-252a e de inibidores de quinase para a prevenção ou o tratamento de patologias associadas a hmgb1
UA105527C2 (uk) Сполука-інгібітор матриптази для лікування раку
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
DK1981851T3 (da) Kinaseinhibitorer og fremgangsmåder til anvendelse deraf
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
MX2007013624A (es) Inhibidores de proteina cinasa.
WO2011041304A3 (en) Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties